Skip to main content
Equibles
OSRH logo

OSRH · OSR Health, Inc.

Track OSRH — free

Use OSRH with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research OSRH.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$0.17 +0.05 (+43.78%) At close · Aug 26
Rebalance outlook locked
Customer concentration — top 3 customers 95% of revenue

3 customers — 95% of revenue

“Three main customers of RMC have in recent years represented approximately 95% of RMC's total sales.”
View the 10-K filed Mar 31, 2026
Market Cap
$4.09M
Shares
35.12M
Volume · Aug 26 4.48M Avg daily vol (3M) 9.94M

Price & Indicators

Drag to pan · scroll to zoom
Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$0.17 Open$0.09 Day$0.08–0.19 52W close$0.12–0.98 Avg vol 30d20.2M Short int1.2M · 3.5% float · 1.4d Short vol38% DataMar 2023–Aug 2026 Filing10-Q · Aug 14

Up next

Latest filing: 10-Q
filed Aug 14, 2026

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$1.81M
Trailing 12 months
Net income (TTM)
−$14.91M
Trailing 12 months
Revenue growth YoY
-72.2%
Year over year
Operating margin
-933.7%
Trailing 12 months
P / E (TTM)
538.0
Trailing earnings · reciprocal yield 0.2%
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$955,553
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+214.2%
Year over year · more shares
Price change (1Y)
-82.9%
Trailing year
Short interest
—
Latest settlement
View all 115 metrics

Equibles Rating

blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical Sell Momentum Very Weak Sentiment Neutral Fundamentals Fair Quant / Vol Very High
Market backdrop VIX 14.8 · calm Equity put/call 0.56
Technical
price trend
Sell
50 / 200-day cross No cross
Price vs 200-day avg −67%
below
Price vs 50-day avg −55%
below
RSI (14) 37
neutral
MACD trend Negative
52-week position 6%
near low
Volume (OBV) Bullish div.
accumulating
Momentum
relative strength
Very Weak
1-month return −65%
trailing
6-month return −64%
trailing
YTD return −70%
this year
Relative strength −77%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $0 › 200d $1 — 200d above 50d
Institutional flow Accumulating
+11% holders QoQ · +7 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
3.48% of float · ▲ +16.5% MoM · 1.4 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
30 holders — mid 3-yr range
Fundamentals
Fair
Revenue growth −18%
Y/Y
Gross margin 20%
contracting
EPS growth +83%
Y/Y
Quant / Vol
risk profile
Very High
Volatility 177%
annualized · 1-yr
Max drawdown −88%
past year
ATR 63.4%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Sell
4 · 2 · 1
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−67% Bearish
Price vs 50-day avg
−55% Bearish
RSI (14)
37 Neutral
MACD trend
Negative Bearish
52-week position
6% Bearish
Volume (OBV)
Bullish div. Bullish
Market signals — smart money & positioning
Mixed
Trend (MA cross) No cross
50d $0 › 200d $1 — 200d above 50d
Institutional flow Accumulating
+11% holders QoQ · +7 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
3.48% of float · ▲ +16.5% MoM · 1.4 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
30 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $0 Now $0 · 6% Range high $1
vs 200-day avg -67% vs 50-day avg -55%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

KPI extraction has been attempted, but no publishable series is available from the examined filings. This is not evidence that the company reports no KPIs.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
OSRH
OSR Health, Inc.
this stock
$4.09M -70.3% -17.7% — 3.5%
VRTX
Vertex Pharmaceuticals Inc / Ma
 $127.55B +12.5% +46.2% 29.3 1.8%
MRNA
Moderna, Inc.
 $89.83B +663.0% +4.3% — 7.7%
REGN
Regeneron Pharmaceuticals, Inc.
 $76.86B -3.3% +20.8% 18.5 2.1%
CSLLY
Csl Ltd
 $61.58B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Reducing
Holders
30
% held
11.6%
Net QoQ
-129.1K sh
Top holder
TORONTO DOMINION BANK
Held Float
View
Held by Funds
Fund positions
4
View
Short & Settlement
Short Interest Rising
Shares short
1.2M
Days to cover
1.4d
Change
+173.3K sh
View
Short Volume
Short vol %
38%
As of
Aug 26, 2026
Short Total
View
Fails to Deliver
FTD shares
533
Value
$229
As of
Jul 28, 2026
View
Off-Exchange
Off-exchange %
63.1%
Week of
Jul 20, 2026
Off-exch Lit
View
Financials
Financials
Revenue (FY)
$2.9M
Net income (FY)
$-2.4M
EPS diluted
$-0.80
View
Filings
SEC Filings
Latest
8-K
Filed
Oct 2, 2026
This year
25
View

Performance

5D 20D 120D MTD YTD
OSRH -55.1% -64.7% -64.3% -62.6% -70.3%
SPY -0.4% +5.0% +12.4% +2.6% +12.3%
vs SPY -54.7% -69.7% -76.7% -65.2% -82.6%
Key facts CIK 1840425 CUSIP 68840D102 13F (30d) 1 filings 1 filers Visit website